FDA approves Cobenfy: A breakthrough Schizophrenia treatment after decades

Quick Summary:

The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults.

This approval introduces a novel pharmacological approach after more than 30 years.

The drug will be available by late October at $1,850 per month before insurance and rebates.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: TOI Business Desk

Category: EconomyBusiness

Markets: IndiaBrazilUnited States

Topics: FDA approval Cobenfy Mental disorder Side effects Schizophrenia treatment Us food and drug administration Bristol Myers Squibb Mental health drug FDA New schizophrenia drug

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-09-27 @ 15:37:06 (3 hours ago)

News Timezone: GMT +5:00

News Source URL: timesofindia.indiatimes.com

Language: English

Article Length: 713 words

Reading Time: 4 minutes read

Sentences: 27 lines

Sentence Length: 27 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Times of India

News ID: 22748146

View Article Analysis

About Times of India

Main Topics: EconomyBusiness

Official Website: timesofindia.indiatimes.com

Update Frequency: 23 posts per day

Year Established: 1838

Headquarters: India

News Last Updated: 4 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Local / Regional

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #28

Publisher Details

Frequently Asked Questions